KR20210054500A - 화합물 - Google Patents

화합물 Download PDF

Info

Publication number
KR20210054500A
KR20210054500A KR1020217000402A KR20217000402A KR20210054500A KR 20210054500 A KR20210054500 A KR 20210054500A KR 1020217000402 A KR1020217000402 A KR 1020217000402A KR 20217000402 A KR20217000402 A KR 20217000402A KR 20210054500 A KR20210054500 A KR 20210054500A
Authority
KR
South Korea
Prior art keywords
compound
compounds
formula
group
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217000402A
Other languages
English (en)
Korean (ko)
Inventor
파멜라 브라운
마이클 도슨
모나 시모노빅
스티븐 보악스
에스더 두퍼치
딘 리버스
로이 레스터
스콧 콜먼
Original Assignee
스페로 테라퓨틱스, 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스페로 테라퓨틱스, 인코퍼레이티드 filed Critical 스페로 테라퓨틱스, 인코퍼레이티드
Publication of KR20210054500A publication Critical patent/KR20210054500A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020217000402A 2018-06-25 2019-06-25 화합물 Pending KR20210054500A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862689602P 2018-06-25 2018-06-25
US62/689,602 2018-06-25
PCT/EP2019/066819 WO2020002325A1 (en) 2018-06-25 2019-06-25 Compounds

Publications (1)

Publication Number Publication Date
KR20210054500A true KR20210054500A (ko) 2021-05-13

Family

ID=67107423

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217000402A Pending KR20210054500A (ko) 2018-06-25 2019-06-25 화합물

Country Status (31)

Country Link
US (3) US11459357B2 (https=)
EP (2) EP4316504A3 (https=)
JP (2) JP7488774B2 (https=)
KR (1) KR20210054500A (https=)
CN (2) CN112789287B (https=)
AR (1) AR116663A1 (https=)
AU (2) AU2019294261B2 (https=)
BR (1) BR112020026663A2 (https=)
CA (1) CA3103158A1 (https=)
CO (1) CO2020016080A2 (https=)
DK (1) DK3810633T3 (https=)
EA (1) EA202092819A1 (https=)
ES (1) ES2971732T3 (https=)
FI (1) FI3810633T3 (https=)
HR (1) HRP20240028T1 (https=)
HU (1) HUE065134T2 (https=)
IL (2) IL279620B2 (https=)
LT (1) LT3810633T (https=)
MA (1) MA52946B1 (https=)
MD (1) MD3810633T2 (https=)
MX (1) MX2020013811A (https=)
PH (1) PH12020552240A1 (https=)
PL (1) PL3810633T3 (https=)
PT (1) PT3810633T (https=)
RS (1) RS65128B1 (https=)
SG (1) SG11202012747VA (https=)
SI (1) SI3810633T1 (https=)
TW (2) TWI851584B (https=)
UA (1) UA128162C2 (https=)
WO (1) WO2020002325A1 (https=)
ZA (1) ZA202301937B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12146004B2 (en) 2014-11-26 2024-11-19 Spero Therapeutics, Inc. Polymyxin compounds and uses thereof
RS65128B1 (sr) * 2018-06-25 2024-02-29 Spero Therapeutics Inc Jedinjenja
WO2022098950A1 (en) 2020-11-06 2022-05-12 Spero Therapeutics, Inc. Compounds
WO2022262823A1 (zh) * 2021-06-18 2022-12-22 华南理工大学 活性氧自由基响应的多粘菌素前药化合物及其应用
CN121426894A (zh) * 2025-07-24 2026-01-30 中国药科大学 一种抗菌肽、药物组合物及应用
CN120699105B (zh) * 2025-08-19 2025-11-21 中国药科大学 一种氘代抗菌肽及其组合物和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2128617A (en) 1982-10-06 1984-05-02 Martti Vaara Polypeptides for use in antibacterial therapy
AU7753787A (en) 1986-08-06 1988-02-24 Jean-Luc Fauchere Production of covalent-linked conjugates from an antibiotic and a non-toxic derivative of polymyxine b
US20010021697A1 (en) 1987-09-14 2001-09-13 Henning Lowenstein Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom, proteinageous or polypeptide components thereof, or analogues of such proteinaceous or polypeptide components
TW274552B (https=) 1992-05-26 1996-04-21 Hoechst Ag
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
CA2540742A1 (en) 2003-09-30 2005-04-14 Terry Hicks Compositions and methods for treating burns
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
BRPI0715095B8 (pt) 2006-08-11 2021-05-25 Northern Antibiotics Oy derivado de polimixina da fórmula geral (i); produto de combinação; composição farmacêutica; método para se sensibilizar bactérias gram-negativas a um agente antibacteriano; método para o desenvolvimento de antibióticos; método para a redução da toxicidade de polimixinas, octapeptinas naturais e seus derivados durante a aplicação das mesmas no tratamento de infecções em um indivíduo; método para melhorar as propriedades farmacocinéticas, de polimixinas, octapeptinas naturais e seus derivados; método para a sensibilização de bactérias gram-negativas clinicamente importantes a um complemento de mecanismo de defesa presente no soro; uso de um derivado; e processo para a preparação de um derivado de polimixina da fórmula (i).
US7807637B2 (en) 2006-08-11 2010-10-05 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
FI20085469A0 (fi) 2008-02-08 2008-05-16 Northern Antibiotics Oy Polymyksiinijohdannaiset, joissa on lyhyt rasvahappohäntä, ja niiden käyttöjä
US8193148B2 (en) 2008-02-08 2012-06-05 Northern Antibiotics Ltd. Short fatty acid tail polymyxin derivatives and uses thereof
US8329645B2 (en) 2008-02-08 2012-12-11 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
ES2334547B1 (es) 2008-09-10 2010-12-03 Universidad De Barcelona Compuestos peptidicos antibacterianos.
CA2747995A1 (en) 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
CN101851270A (zh) 2009-04-03 2010-10-06 梁浩 一种多粘菌素衍生物及其制备方法
WO2010130007A1 (en) 2009-05-14 2010-11-18 Monash University Antimicrobial compounds
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2012051663A1 (en) 2010-10-21 2012-04-26 Monash University Antimicrobial compounds
WO2012168820A1 (en) * 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin derivatives useful as antibacterial agents
CA2855916A1 (en) 2011-11-18 2013-05-23 Novacta Biosystems Limited Polymyxin derivatives
KR102354902B1 (ko) 2013-05-22 2022-01-24 에버레스트 메디신즈 (싱가포르) 피티이. 리미티드 폴리믹신 유도체 및 상이한 항생제와의 조합 요법에 있어서의 이들의 용도
MX359104B (es) 2014-03-11 2018-09-14 New Pharma Licence Holdings Ltd Derivados de polimixina y su uso en terapia de combinacion junto con diferentes antibioticos.
JP2017512818A (ja) 2014-04-01 2017-05-25 モナシュ、ユニバーシティＭｏｎａｓｈ Ｕｎｉｖｅｒｓｉｔｙ 抗菌性化合物としてのポリミキシン誘導体
US12146004B2 (en) 2014-11-26 2024-11-19 Spero Therapeutics, Inc. Polymyxin compounds and uses thereof
SG11201704627XA (en) * 2014-12-17 2017-07-28 Hoffmann La Roche Enzymatic one-pot reaction for double polypeptide conjugation in a single step using sortase
WO2016166103A1 (en) * 2015-04-13 2016-10-20 Xellia Pharmaceuticals Aps Polymyxin derivatives
EP3356387B1 (en) * 2015-09-29 2024-06-26 Monash University Antimicrobial polymyxin derivative compounds
US10428122B2 (en) * 2016-06-16 2019-10-01 International Aids Vaccine Initiative, Inc. Tuberculosis compositions and methods of treating or preventing tuberculosis
RS65128B1 (sr) * 2018-06-25 2024-02-29 Spero Therapeutics Inc Jedinjenja
WO2020014501A1 (en) 2018-07-11 2020-01-16 Cidara Therapeutics, Inc. Compositions and methods for the treatment of bacterial infections

Also Published As

Publication number Publication date
EP4316504A2 (en) 2024-02-07
JP2024109664A (ja) 2024-08-14
FI3810633T3 (fi) 2024-02-09
SG11202012747VA (en) 2021-01-28
IL279620B1 (en) 2025-11-01
US20260103491A1 (en) 2026-04-16
PT3810633T (pt) 2024-02-19
TW202019949A (zh) 2020-06-01
ZA202301937B (en) 2023-09-27
ES2971732T3 (es) 2024-06-06
JP7488774B2 (ja) 2024-05-22
MD3810633T2 (ro) 2024-05-31
CN112789287A (zh) 2021-05-11
US20230012121A1 (en) 2023-01-12
EP4316504A3 (en) 2024-04-17
IL279620B2 (en) 2026-03-01
DK3810633T3 (da) 2024-01-15
EA202092819A1 (ru) 2021-05-21
SI3810633T1 (sl) 2024-04-30
EP3810633A1 (en) 2021-04-28
IL323560A (en) 2025-11-01
CN112789287B (zh) 2024-06-21
US12528837B2 (en) 2026-01-20
PL3810633T3 (pl) 2024-04-08
CO2020016080A2 (es) 2021-01-18
MX2020013811A (es) 2021-03-09
RS65128B1 (sr) 2024-02-29
US20210246169A1 (en) 2021-08-12
AR116663A1 (es) 2021-06-02
JP2021528449A (ja) 2021-10-21
MA52946A (fr) 2021-04-28
HRP20240028T1 (hr) 2024-03-29
MA52946B1 (fr) 2024-03-29
CA3103158A1 (en) 2020-01-02
AU2019294261B2 (en) 2024-02-29
US11459357B2 (en) 2022-10-04
TWI851584B (zh) 2024-08-11
HUE065134T2 (hu) 2024-05-28
AU2024203362A1 (en) 2024-06-06
LT3810633T (lt) 2024-01-10
UA128162C2 (uk) 2024-04-24
CN118878638A (zh) 2024-11-01
TW202446783A (zh) 2024-12-01
PH12020552240A1 (en) 2021-08-16
WO2020002325A1 (en) 2020-01-02
AU2019294261A1 (en) 2021-02-04
BR112020026663A2 (pt) 2021-03-23
IL279620A (en) 2021-03-01
EP3810633B1 (en) 2023-12-13
NZ771833A (en) 2024-09-27

Similar Documents

Publication Publication Date Title
US12528837B2 (en) Aryl substituted polymyxin derivatives
KR102354902B1 (ko) 폴리믹신 유도체 및 상이한 항생제와의 조합 요법에 있어서의 이들의 용도
RU2740190C2 (ru) Производные полимиксина и их применение в комбинированной терапии совместно с различными антибиотиками
US20230340026A1 (en) Compounds
CN103946233A (zh) 多黏菌素衍生物
HK40098322A (en) Compounds
HK40040020A (en) Compounds
HK40040020B (en) Compounds
EA047835B1 (ru) Соединения
TW202233649A (zh) 化合物
HK1221474B (en) Polymyxin derivatives and their use in combination therapy together with different antibiotics

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000